REGN•benzinga•
Regeneron Touts Encouraging Early Data From Investigational Gene Therapy For Rare Form Of Hearing Loss
Summary
Regeneron's DB-OTO gene therapy shows improved hearing in 10 of 11 children in the CHORD trial, with three reaching near-normal levels at 24 weeks.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 25, 2025 by benzinga